Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Logan Capital Management Inc.

Logan Capital Management Inc. increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 4.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,904 shares of the specialty pharmaceutical company’s stock after acquiring an additional 180 shares during the period. Logan Capital Management Inc.’s holdings in Jazz Pharmaceuticals were worth $480,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of JAZZ. Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $89,175,000. Armistice Capital LLC grew its position in Jazz Pharmaceuticals by 108.4% in the 4th quarter. Armistice Capital LLC now owns 651,626 shares of the specialty pharmaceutical company’s stock valued at $80,150,000 after buying an additional 338,882 shares in the last quarter. Pacer Advisors Inc. increased its stake in Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after buying an additional 224,865 shares during the period. Aristotle Capital Management LLC bought a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter worth about $22,748,000. Finally, Baupost Group LLC MA lifted its stake in shares of Jazz Pharmaceuticals by 23.7% in the 4th quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock worth $102,545,000 after acquiring an additional 160,000 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now owns 36,629 shares in the company, valued at approximately $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently commented on JAZZ. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, May 31st. Needham & Company LLC reaffirmed a “buy” rating and set a $222.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, May 2nd. Royal Bank of Canada restated an “outperform” rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, February 29th. Barclays cut their target price on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Finally, Truist Financial reiterated a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $190.92.

Get Our Latest Stock Analysis on JAZZ

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $108.99 on Tuesday. The business’s 50-day simple moving average is $109.70 and its 200-day simple moving average is $117.64. Jazz Pharmaceuticals plc has a 52 week low of $103.01 and a 52 week high of $146.70. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. The firm has a market cap of $6.87 billion, a price-to-earnings ratio of 22.47, a P/E/G ratio of 1.72 and a beta of 0.62.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. The firm had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. As a group, equities research analysts expect that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Featured Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.